Previous studies have shown that tumor necrosis factor alpha (TNF-a) plays a pathophysiologic role in sepsis induced in rat pups by group B streptococci (GBS). In this model, TNF-a is also partially responsible for the induction of interleukin-6 (IL-6). The present study was undertaken to investigate the role of IL-6 in neonatal BALB/c mice infected with type III GBS. The effect of anti-IL-6 monoclonal antibodies and recombinant IL-6 on lethality and TNF-a production was investigated. In mouse pups infected with GBS strain COH1, plasma IL-6 reached levels of 3,067 ± 955 and 1,923 ± 891 U/ml when measured at 22 and 48 h, respectively (P < 0.05 compared with uninfected controls). Pretreatment with 25 ,ug of anti-IL-6 antibodies totally prevented the increase in circulating IL-6 bioactivity at both 22 and 48 h after infection (P < 0.05).
Interleukin 6 (IL-6) is one of the major mediators of the immune system's acute responses to any infectious or inflammatory stimulation (34) . This cytokine is produced by both lymphoid and nonlymphoid cells and has been shown to regulate proliferation and differentiation of T (17, 30) and B (16) lymphocytes and hematopoietic stem cells (6, 41) . In addition, IL-6 is a major mediator of the acute-phase response, mediating the synthesis and release of a variety of acute-phase proteins in the liver (11, 24) .
The role of IL-6 in various infectious processes is not yet well understood. Elevated levels of IL-6 are present in serum and tissues during experimental infections of mice with Listeria monocytogenes (15) , mycobacteria, and brucellae (28) . Endotoxins are known to activate IL-6 synthesis (9, 23) , and the levels of and other cytokines such as tumor necrosis factor alpha (TNF-a) and IL-1 are elevated in septic adults (14) and infants (7, 13, 22) .
In some gram-positive and gram-negative bacterial sepsis models, lethality and pathophysiologic changes are mediated by TNF-o (10, 33) and IL-1 (2, 25) . Less is known about the role of IL-6 in septic shock models. Administration of anti-IL-6 monoclonal antibody produced divergent effects in two gramnegative shock models. Anti-IL-6 protected mice against a lethal Escherichia coli challenge, suggesting a pathophysiologic role for this cytokine (29) . However, anti-IL-6 enhanced endotoxin-induced lethality in galactosamine-sensitized mice when TNF-ac activity was partially blocked by limited doses of anti-TNF-a (3).
We have previously documented that TNF-a plays a pathophysiologic role in sepsis induced in rat pups by group B streptococci (GBS), a major human neonatal pathogen (19, 31) . In this model, plasma levels of TNF-ot and other cytokines, including IL-6, correlate with sepsis severity. In addition, TNF-a is at least partially responsible for the induction of IL-6, as evidenced by a reduction in circulating IL-6 bioactivity following neutralization of TNF-a by specific antibodies (31) . The present study was undertaken to investigate the role of IL-6 in experimental GBS sepsis. The effect of anti-IL-6 antibodies and recombinant IL-6 (rIL-6) on lethality and TNF-a production in septic neonatal mice was investigated. Neonatal mice rather than rats were used because of the wider availability of mouse-specific reagents and the opportunity to use smaller quantities of these reagents. Previous studies have shown that GBS infections in neonatal mice and rats have a similar clinical course, histopathologic features, (26) , and cytokine release (32 (Calco, Italy). Pups from each litter were randomly assigned to control or experimental groups, marked, and kept with the mother.
Bacteria. GBS strains COH1 and COH31, originally isolated from septic neonates, were kindly provided by Craigh Rubens, University of Washington, Seattle (20) . Strain COH1 produces higher amounts of type III capsular polysaccharide and is more virulent than strain COH31 in animals (19, 20, 32 TNF-a and IL-6 measurements. To measure circulating levels of TNF-ot and IL-6, groups of 10 animals were killed by decapitation under ether anesthesia at different times after challenge with viable bacteria. Mixed venous-arterial blood was collected in heparinized containers and centrifuged after saving 10 RI for colony counts. These were performed by standard pour plate methods. Pooled plasma from two animals (50 to 70 Rd) was stored at -70°C until assayed for TNF-at and IL-6 activity by cytotoxicity with L929 murine fibroblasts, and B9 proliferation assays, respectively, as previously described (31) .
TNF-at activity was expressed in units per milliliter, 1 U being defined as the amount of cytokine causing 50% lysis of L929 cells. Six serial twofold dilutions (final dilutions, 1:20 to 1:640) were tested in duplicate for each sample. The assay was calibrated by using murine recombinant-TNF-a (specific activity, 20 U/ng; Genzyme) as a standard. TNF-a activity in selected plasma samples was totally inhibited by a 1:100 dilution of rabbit anti-murine TNF-ao serum but not by normal rabbit serum.
IL-6 activity was also expressed in units per milliliter, 1 LD90s of type III GBS strain COHL. Plasma was collected at various times after challenge from pups (10 per group) pretreated intraperitoneally with vehicle (U) or 25 pug of anti-mouse IL-6 MAb (0) at 6 h before challenge. Points and bars represent means ± standard deviations for five observations. Each observation was conducted on pooled plasma samples from two pups. *, significantly (P < 0.05) different from vehicle controls by one-way analysis of variance and the StudentNewman-Keuls test.
sessed by the two-tailed Fisher exact test. With both tests, differences were considered significant when P values were <0.05.
RESULTS
Elfects of anti-IL-6 antibodies. Figure 1 depicts plasma IL-6 levels in neonatal mice pretreated with 25 jig of anti-IL-6 MAb and in vehicle-treated controls at 12, 22, and 48 h after challenge with 5 LD90s of strain COHL. Plasma IL-6 values were 19 ± 9 U/ml (n = 10) in uninfected controls (not shown). In infected controls, IL-6 levels were significantly increased to 3,067 ± 955 and 1,923 ± 891 U/ml (P < 0.05 compared with uninfected controls) when measured at 22 and 48 hours, respectively, as observed previously in neonatal rats (31) . Pretreatment with anti-IL-6 MAb totally prevented the increase in circulating IL-6 bioactivity at both 22 and 48 h after infection (P < 0.05) (Fig. 1) .
In further experiments, the effect on lethality of the same anti-IL-6 treatment was investigated. To verify whether consistent results would be obtained using different bacterial numbers as a challenge, mouse pups were infected with 1 and Effect of II16 and anti-IL-6 on plasma TNF-a levels and CFU. Because IL-6 can modulate TNF-a production (1), the effects of IL-6 or anti-IL-6 on circulating TNF-at levels in septic pups were investigated. Plasma TNF-ax concentrations were below the detection limit in uninfected and baseline controls (n = 10; not shown). Figure 3 shows TNF-a levels in control and treated mice at various times after infection with 5 LD90s of strain COHL. TNF-a elevations (P < 0.05 compared with baseline controls) were measured at 12, 22, and 48 h after GBS challenge in untreated animals (68 ± 28, 233 + 98, and 98 ± 34 U/ml, respectively). Pretreatment with IL-6 significantly (P < 0.05) decreased TNF-ot levels at 12 and 22 h by 55 and 69%, respectively. Anti-IL-6 had an opposite effect, as evidenced by a 145% increase (P < 0.05) in TNF-ot levels at 48 h after challenge.
Since experimental abrogation of TNF-ot activity was beneficial in septic rat pups (31) , the effects on lethality of IL-6 were compared with those of anti-TNF-ot. Table 3 shows that rIL-6 and anti-TNF-ot had similar effects in increasing survival at 48 and 72 h (P < 0.05). However, combined treatment with these agents did not afford any further protection over treatment with IL-6 or anti-TNF-ot alone (Table 3) .
CFU counts performed on blood samples obtained from animals treated with IL-6 (12,500 U) or anti-IL-6 (25 jig) 6 h before challenge with 5 LD90s of strain COH1 did not reveal significant differences among the experimental groups (data not shown). 
DISCUSSION
Cytokine mediators may play major roles in the pathophysiology of septic shock induced by either gram-negative or gram-positive bacteria. While TNF-ct has a protective role in localized infections and in diseases caused by intracellular bacteria, high circulating TNF-ot and IL-1 levels can produce detrimental inflammatory and hemodynamic responses, leading to multiorgan failure and death (36) . The role of IL-6 in septic shock is highly controversial. Because IL-6 decreases TNF-a production (1) and the expression of TNF receptors in macrophages (4), it can be considered mainly anti-inflammatory. In addition, IL-6 is the main inducer of hepatic acutephase proteins, many of which may bind and inactivate proinflammatory mediators, thereby mitigating the course of septic shock (35, 37) . IL-6 also induces adrenocorticotropin and, in turn, cortisol, a potent anti-inflammatory hormone (40) .
The effects of experimental abrogation of endogenous IL-6 with specific antibodies varied in two gram-negative sepsis models (3, 29) . Although in both of these models lethality could be totally prevented by anti-TNF-ot antibodies, anti-IL-6 protected mice against lethal challenges with E. coli or rTNF-ot (29) but had no effect in galactosamine-sensitized mice challenged with endotoxin (3). In the latter study, anti-IL-6 and IL-6 enhanced and decreased, respectively, lethality when TNF-ao was partially neutralized by limited anti-TNF-ot doses.
Little is known about the role of IL-6 in neonatal or gram-positive sepsis. Since anti-TNF-ao antibodies or blocking compounds are beneficial in animal models of GBS disease (12, 31), we hypothesized that modulating TNF-ot production by the administration of rIL-6 or anti-IL-6 would affect lethality. Results show that neutralization of endogenous IL-6 can result in a moderate decrease in survival time of neonatal mice rendered septic with GBS. This effect was associated with increased TNF-ao levels at 48 h after challenge. Conversely, exogenous IL-6 markedly reduced TNF-a levels and prolonged survival. Since TNF-ot is involved in IL-6 induction (31), our data support the hypothesis that IL-6 participates in a negative feedback loop regulating TNF-ot levels during GBS sepsis. This is in agreement with observations in adult mice infected with E. coli (29) . In that model, anti-IL-6 increased TNF-ot levels, while anti-TNF-ot decreased IL-6 levels. Monocytes from very small premature (42) but not term (21, 27, 43) infants show defective production of IL-6 in response to GBS and other pathogens. The production of TNF-a was also reported to be lower in premature neonates (8, 38) . However, mixed mononuclear cell from term neonates were recently shown to produce more TNF-ac than those from adults in response to GBS (39) . Thus, the possibility that altered regulation of TNF-ot and other inflammatory mediators plays a role in the pathophysiology of neonatal sepsis should be considered in future studies.
Since IL-6 has pleiotropic effects on a number of different cell types, our data cannot exclude the possibility that mechanisms other than down regulation of TNF-ot may contribute to or even be predominant in the effects of IL-6 in our model. The induction of an acute-phase response by low doses of rIL-6 did not alter the lethality of galactosamine-sensitized or normal mice challenged with endotoxin (5). Since, in the present study, the minimal effective dose of IL-6 was approximately 16-fold greater than that employed to induce the acute-phase response in adult (5) and neonatal (32) mice, it is unlikely that the latter effect of IL-6 contributed to increased survival. Further studies will be needed to assess whether IL-6-induced modulation of cortisol and acute-phase protein responses plays a role in GBS sepsis. IL-6 pretreatment has been shown to prime host defenses against infection with the facultative intracellular pathogen L. monocytogenes, resulting in decreased bacterial numbers in the spleen and liver (18) . As in the present study, timing of administration relative to challenge was crucial, as evidenced by lack of effects when the cytokine was given at the time of or after infection. In our study, no differences in bacterial numbers were noted between IL-6-treated and control mice. This may relate to differences in the defense mechanisms against facultative intracellular and encapsulated bacteria or in the time course of the infections. In the Listeria study, the more significant differences were observed at 4 days after infection, a time at which lethality approaches 100% in the GBS model. It should be noted, however, that the doses used in the Listeria study were at least 20-fold higher than the ones presently used. Thus, it cannot be excluded that IL-6 at high doses can increase host defenses against GBS as well.
Future studies will be needed to assess whether IL-6 can prove effective in the therapy of GBS diseases in conjunction with antibiotics, supportive measures, and, possibly, other anti-inflammatory agents.
